Spread the love

A study from the Clinic for Endocrinology, Diabetes & Metabolism and Department Biomedicine, University Hospital Basel, Basel, Switzerland shows that Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.” This study was published in the 30 October  2011 issue of the journal “Nature Medicine” [the number 1 journal in General Medicine with an I.F of 24.973] by Prof. Donath MYEllingsgaard H and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for T2DM: MiRNA-25 enhances insulin secretion by increasing glucagon-like peptide-1 secretion via down regulation of its target gene. 

Significance:

 Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment is required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find a way to induce regeneration of adult β-cells that were lost in DM.

This study suggests, for the first time, that MiRNA25, by decreasing the expression of its target gene, it may increase glucagon-like peptide-1 secretion.  Thereby, it may increase (1) insulin secretion from L cells and alpha cells;  and (2) induce regeneration of insulin-secreting cellsThus, pharmacological formulations encompassing “miRNA-25 activators” may be used to trat DM. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for T2DM: MiRNA-25 enhances insulin secretion by increasing glucagon-like peptide-1 secretion via down regulation of its target gene, 14/May/2015, 13.30,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org


Spread the love